ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

ObsEva To Increase Issued Share Capital by Creating Additional Treasury Shares

ObsEva SA (OBSV) delivered earnings and revenue surprises of 7.14% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ObsEva SA (OBSV) Reports Q3 Loss, Lags Revenue Estimates

ObsEva Announces Third Quarter 2022 Financial Results and Provides a Business Update

ObsEva Announces Sale of Ebopiprant License Agreement to XOMA for up to $113 Million

ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings

ObsEva Announces IND Approval for Yuyuan Bioscience's Phase 1 Clinical Trial of Nolasiban in China

ObsEva Announces Progress on Restructuring Initiatives

American Virtual Cloud Technologies

Blue Water Vaccines

Here's what you need to know about trading penny stocks on August 30th The post Hot Penny Stocks For Your Buy List in September? 3 to Watch  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks For Your Buy List in September? 3 to Watch

ObsEva Receives Nasdaq Non-Compliance Notice

ObsEva Files Second Quarter 2022 Financial Statements

ObsEva SA (OBSV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About ObsEva SA (OBSV) Rating Upgrade to Buy

ObsEva Announces $31 million Debt Retirement and $11 million Debt Refinancing

ObsEva Announces Management Change

Biopharmaceutical company ObsEva (NASDAQ: OBSV ) is trending today, but not necessarily in a good way. The company issued a corporate update press release early this morning.

Why Is ObsEva (OBSV) Stock Down 70% Today?

ObsEva Announces Corporate Updates

Regulatory approval was achieved of Yselty for the treatment of women with uterine fibroids in the European Union. Regulatory approval was achieved of Yselty for the treatment of women with uterine fibroids in the United Kingdom.

ObsEva: Ignored, But Long-Term Prospects Exist On Recent Progress

Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy

ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

ObsEva's (OBSV) Yselty receives its first marketing approval in the European Union for the treatment of uterine fibroids in adult women. Shares were up 11% in pre-market trading following the news.

ObsEva's (OBSV) Yselty Gets EU Nod to Treat Uterine Fibroids

- Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy -

ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

LONDON--(BUSINESS WIRE)--The European Commission (EC) has granted Marketing Authorization for Yselty® (linzagolix), an oral GnRH antagonist, indicated for the treatment of moderate to severe symptoms of Uterine Fibroids (UF) in adult women (over 18 years of age) of reproductive age. This announcement is in partnership with ObsEva SA (Nasdaq: OBSV), a biopharmaceutical company developing and commercializing novel therapies for women's health. The EC decision follows the Committee for Medicinal P

Theramex Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Symptoms of Uterine Fibroids

-Data featured in two oral presentations at the 8th Society of Endometriosis and Uterine Disorders Congress and a poster presentation at the International Society of Gynecological Endocrinology 20 th World Congress -

ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses

GENEVA, Switzerland May 1 9 , 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced the appointment of Annette Clancy as Chair of the Board of Directors at the Company's Annual General Meeting on May 18, 2022. Ms. Clancy has served as a member of ObsEva's Board of Directors since 2013 and was previously Chair from November 2013 to December 2016. Ms. Clancy succeeds Dr. Frank Verwiel, who had decided to step down from the role of Chair and retire from the Board of Directors, effective following the conclusion of the Annual General Meeting.

ObsEva Announces Appointment of Annette Clancy as Chair of the Board of Directors

ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2022 Annual General Meeting held on May 18, 2022

ObsEva SA (NASDAQ:OBSV ) Q1 2022 Results Conference Call May 17, 2022 8:00 AM ET Company Participants Katja Buhrer - Chief Strategy Officer Brian O'Callaghan - Chief Executive Officer Brandi Howard - Chief Clinical Officer Will Brown - Chief Financial Officer Clive Bertram - Chief Commercial Officer Conference Call Participants Ed Nash - Canaccord Nathan Weinstein - Aegis Capital Operator Good day, ladies and gentlemen, and welcome to the ObsEva First Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen only mode.

ObsEva SA (OBSV) CEO Brian O'Callaghan on Q1 2022 Results - Earnings Call Transcript

Foresight Autonomous Hlds

Imperial Petroleum

Kintara Therapeutics

Mullen Automotive

Regulus Therapeutics

These penny stocks all have 10x potential or greater during the remainder of 2022. They are risky but relatively straightforward.

7 Penny Stocks With 10x Potential This Year

News for ObsEva Stock (OBSV)